{
  "retracted": false,
  "timestamp": 1482364800000,
  "updates": [
    {
      "timestamp": 1574165408625,
      "identifier": {
        "doi": "10.1182/blood-2016-11-750505"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1182/blood-2013-02-485888"
  },
  "journal": "Blood",
  "publisher": "American Society of Hematology",
  "title": "Cervantes F, Vannucchi AM, Kiladjian J-J, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053."
}
